Trastuzumab Deruxtecan (Enhertu)

Type: drug

Status: FDA/EMA Approved

Developer: Daiichi Sankyo/AstraZeneca

Breakthrough Summary

No summary available.

Mechanism of Action

Antibody-drug conjugate for HER2-low breast cancer

Year: 2022+